Acute Therapies at Baxter - Global’s Post

Why use ECCO2R in patients with acute respiratory distress syndrome (ARDS)? Watch this 1-minute highlight from ISICEM 2024 in which Professor Alain Combes discusses potential benefits of ECCO2R, including decreased ventilator-induced lung injury. To learn more, watch the full symposium "Advancing What's Possible in Critical Care": https://ow.ly/TeCo50RTlrj ISICEM 2024 = 43rd International Symposium on Intensive Care & Emergency Medicine in Brussels, Belgium on March 19-22, 2024. Baxter is a trademark of Baxter International Inc. GBU-AT00-240011 (v2.0) 05/2024 #AcuteTherapies #OrganSupportTherapies #Baxter #CriticalCare #ISICEM2024 #ECCO2R

To view or add a comment, sign in

Explore topics